urban-gro Secures $25M Highly Dilutive Equity Line and $105K Loan Amidst Nasdaq Compliance Efforts

summarizeSummary

urban-gro, Inc. secured a $25 million highly dilutive equity line of credit and a $105,000 term loan, crucial for immediate liquidity and ongoing efforts to meet Nasdaq listing requirements following a recent reverse stock split and worsening financials.

check_boxKey Events

• Secures $25M Equity Line of Credit (ELOC)

  The company entered an agreement with Hudson Global Ventures, LLC, allowing it to sell up to $25 million of common stock over 24 months. The pricing is highly dilutive, set at 90% of the lowest traded prices during specified periods, indicating a 'death spiral' financing structure.

• Issues Warrants as ELOC Consideration

  As consideration for the ELOC, urban-gro issued 55,556 common stock purchase warrants to the investor with an exercise price of $12.50 per share (post-reverse split adjusted), along with a $20,000 payment for legal counsel.

• Obtains $105K Term Loan

  The company also secured a $105,000 term loan from Agile Capital Funding, LLC and Agile Lending, LLC, intended for general working capital and vendor payments to comply with Nasdaq requirements. This loan has a 28-week term and includes a $5,000 administrative fee.

• Financing Follows Reverse Stock Split and Distress

  This financing package comes shortly after the company's 1-for-25 reverse stock split (effective Feb 9, 2026) and amidst ongoing financial challenges, including loan defaults and Nasdaq delisting threats, as previously disclosed in recent filings.

auto_awesomeAnalysis

urban-gro, Inc. has secured a new equity line of credit (ELOC) for up to $25 million and a $105,000 term loan, signaling continued financial distress and a desperate attempt to maintain Nasdaq compliance. The ELOC, with its variable pricing mechanism tied to the lowest traded prices, is highly dilutive and indicative of the company's weak bargaining position. This follows a recent 1-for-25 reverse stock split and a prior small capital raise at a deep discount, both aimed at avoiding Nasdaq delisting. The $105,000 loan, while small, is earmarked for critical working capital and vendor payments to meet Nasdaq requirements, highlighting immediate liquidity challenges. The company's agreement not to pursue other dilutive financing without investor consent further restricts its future capital-raising options. This financing provides a short-term lifeline but at a potentially severe cost to existing shareholders through significant dilution.